缬沙坦加参麦注射液治疗充血性心力衰竭的临床观察(PDF)
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2007年第2期
- 页码:
- 202-204
- 栏目:
- 临床研究
- 出版日期:
- 2007-04-01
文章信息/Info
- Title:
- Clinical study on effect of Valsartan and Shenmai Injection in treating congestive heart failure
- Author(s):
- ZHANG Jiming; HOU Zhaorong
- Institute Center of Coronary Artery Disease,Jining Hospital,Shandong Academy of Medical Sciences, Jinan 250001, Shandong, China
- 分类号:
- R541.61
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 目的 观察缬沙坦（Valsartan）加参麦注射液(Shenmai Injection,SI)对充血性心力衰竭(CHF)心肌损害的疗效。 方法 采用随机分组的方法，分别用常规治疗（31例）和缬沙坦、SI加常规治疗（31例），并对CHF的各项实验室指标［血浆肌钙蛋白T(cTnT)、心肌酶谱］进行观察。 结果 在CHF进程中，cTnT浓度随着心功能恶化呈进行性增高。应用缬沙坦加SI治疗2周后，患者左室收缩功能得到明显改善，未发现严重不良反应。结论 血浆cTnT可作为CHF患者预后判断的一项重要生化指标。缬沙坦加SI是治疗CHF安全有效的药物。
- Abstract:
- AIM To observe the therapeutic effect of Valsartan and Shenmai Injection (SI) in treating congestive heart failure (CHF). METHODS The changes in serum cardiac troponin T (cTnT), a specific marker reflecting myocardial injury, creatine kinase (CK) and creatine kinase isoenzyme (CKMB) were simultaneously monitored in 62 chronic CHF patients. The subjects were randomized into two groups, the routine treatment group and the routine treatment + Valsartan + SI group, and the therapeutic effect of the two groups was compared. RESULTS The serum cTnT level progressively increased along with heart function deterioration. After treated with Valsartan and SI for 2 weeks, the hemodynamics of the CHF patients got stable and their heart function improved obviously. No serious adverse reaction was found in the therapeutic course. CONCLUSION The level of serum cTnT can be taken as a reliable biochemical parameter to predict the prognosis of CHF patients. Valsartan plus SI is safe and effective in treating CHF.
参考文献/References
［1］ Braunwald E (陈灏珠主译). 心脏病学［M］. 第5版.北京：人民卫生出版社，2001：363.
［2］ 叶任高. 内科学［M］. 第5版.北京:人民卫生出版社，2000：345-347.
［3］ Lloyd Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the framingham heart Study［J］. Circulation, 2002,106(24):3068-3072.
［4］ The Cardiac Insufficiency Bisoprolol Study Ⅱ(CIBISⅡ ):a random isedtrial［J］. Lancet,1999,353(9146):9-13.
［5］ 龙明智，黄峻，王军，等.扩张型心肌病心肌β受体敏感性及其与心肌损害的关系［J］.中华心血管病杂志, 1999,27（6）：466-467.
［6］ Armin H, Seigo I. Apoptosis: Basic mechanisms and implications for cardiovascular disease［J］. Circ Res,1998,82(11):1111-1129.
［7］ 翟桂兰，祝焕林，王庆茹，等. 缬沙坦对心力衰竭患者心肌重构的影响J］.心脏杂志, 2005,17（6）：567-569.
［8］ 李景，程何祥，贾国良，等. 替米沙坦治疗扩张型心肌病并发心功能不全的疗效评价［J］.心脏杂志, 2006,18（4）：427-429.
［9］ 阎爱国，荣芳，李丽. 伊贝沙坦联合培哚普利治疗充血性心力衰竭临床观察［J］.心脏杂志, 2005,17（2）：145-146.
［10］金先桥，段生福，牛汝楫,等.参麦注射液及其配伍对慢性缺氧鼠血气及血流动力学的影响［J］.中国中西医结合杂志, 1995,15（3）：162-164.
备注/Memo
- 备注/Memo:
- 收稿日期：2006-02-17.通讯作者：张继明，副主任医师,主要从事心血管疾病研究 Email：zjm63823@163169.net
常用功能
统计/Statistics
- 摘要浏览/Viewed1430
- 全文下载/Downloads914
- 评论/Comments
